Search papers, labs, and topics across Lattice.
1HEOR, Daiichi-Sankyo, Basking Ridge, NJ
1
0
0
3
Earlier use of trastuzumab deruxtecan (T-DXd) in the second-line setting for HER2+ metastatic breast cancer is associated with improved duration of therapy, progression-free survival, and overall survival compared to later-line use.
